Mobile
  • Search
  • Advanced search
  • Multi-criteria search
  • Who are we ?
  • Log in
  • Sign up
  • Français
  • English

Kusajili – Clinical trials directory

Your research

Clear all filters

Filtres
organs
Specialty
Type
Promoter
  • Abbott GmbH & Co. KG (1)
Country
Source
  • euctr (1)
Phase
  • complete (1)

Promoter: Abbott GmbH & Co. KG
Abbott GmbH & Co. KG Update Il y a 4 ans

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain To compare the analgesic efficacy and the safety of ABT-894 (1 mg, 2 mg, or 4 mg capsules) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pain (DNP). Duloxetine 60 mg administered once daily (QD) will be assessed for assay sensitivity.

  • Country None
  • organs None
  • Specialty None
Closed trial
More information

  • 1

Who are we ?

Kusajili was created to respond to a request from physicians to simplify access to patient registries and inclusion. Kusajili is regularly updated according to new French and international trials. [email protected]

Kusajili and MyHomeDoctor

MyHomeDoctor software unique to the world, created with surgeons, for follow-up and analysis of patient follow-up. Kusajili and MyHomeDoctor partners, help clinical research through improved patient follow-up and automatic inclusion.

Sign up

Sign up
Français - English - CGU - Cookies

©2023 Kusajili France - Kusajili International - MedSynApps - MyHomeDoctor.